The Readout Loud

• 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

  We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

  --------  

  34:45
• 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

  Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.). But first, we chat about Akero Therapeutics and the results reported this week from a study of its experimental drug that showed, for the first time, reversal of cirrhosis in patients with severe MASH. We critique that Hims & Hers commercial. And lastly, we talk about a new fund from biotech VC Curie.Bio and the money it’s invested in a still-stealthy gene therapy company trying to tackle ALS.

  --------  

  34:29
• 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

  We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporter Helen Branswell joins us to explain the implications of Trump's decision to pull the U.S. out of the WHO.

  --------  

  33:09
• 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

  We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the industry.

  --------  

  58:47
• 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

  We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

  --------  

  33:21

Weitere Wirtschaft Podcasts

Trending Wirtschaft Podcasts

Über The Readout Loud

The Readout Loud: Zugehörige Podcasts